Storytelling is a part of J Freireich’s legacy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

J enjoyed explaining that the letter J in his name appeared in his birth certificate.

Emil J Freireich in 2016.
Photo courtesy of MD Anderson Cancer Center

He had no idea why his mother, an immigrant seamstress at a Chicago sweatshop, put it there, but it was certainly not an abbreviation for an actual name, Jacob, for example.

J’s J was its own thing. No period was to be used.

Great stories beautifully told are a part of J’s legacy. He spoke with reporters and historians, leaving behind more primary source material than your average Joe.

Emil J Freireich died Feb. 1, aged 93, at MD Anderson Cancer Center.

Here are J’s stories in his own words:

  • Freireich’s conversation with Daniel Hayes, a breast cancer expert at the University of Michigan and former president of the American Society of Clinical Oncology, is particularly entertaining.

  • There is also a beautifully annotated, three-session, seven-hour oral history done by MD Anderson.

  • NIH historians, too, sat down with Freireich. The interview appears here.

  • Another fine resource is a book by John Laszlo, “The Cure of Childhood Leukemia: Into the Age of Miracles.” Laszlo, both a participant and a historian of these events, records a lengthy conversation with Freireich and makes it a part of the narrative.

In this issue, we supplement J’s storytelling with an obituary by MD Anderson, and appreciations by Hagop Kantarjian, Moshe Talpaz, and Otis Brawley.

Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login